Almirall says ADlong extension trial shows lebrikizumab sustains EASI-75 response in 92.9% at week 108

By Public Technologies
  • Almirall disclosed late-breaking long-term data from the Phase 3b ADlong extension study of lebrikizumab in atopic dermatitis.
  • Results were presented at EADV 2026, tracking patients for up to five years of continued treatment exposure.
  • The update showed sustained disease control over time, supporting durable symptom relief in moderate-to-severe patients.
  • Safety remained consistent with earlier trials, with no new long-term safety signals flagged in the follow-up.
  • The readout strengthens the product’s long-term evidence base in Europe, where it is marketed as Ebglyss.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.